This one deals with the requisite post-market aspects (surveillance, complaint remediation, etc).
For a Medical Tech. start-up to fail on post-market surveillance is in-excusable. Move Fast & Break Things should not apply to people's health and medications.
There is something very wrong when a company with that much cash fails BOTH in pre & post market situations.